Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GSK to close Dartford facility
The proposed closure, which is subject to consultation with trade union and staff representatives, would result in the loss of around 620 established roles at the Dartford site
The proposed closure, which is subject to consultation with trade union and staff representatives, would result in the loss of around 620 established roles at the Dartford site
According to the company, the new ‘PyroMark Q24 K-ras assay-kit’ is able to detect all major and minor known mutations in the K-ras codons 12, 13 and 61,
Ms Parker remains on the board of directors. Ms Robinson joined Targeted Genetics in March 2000 and previously served as vice president of business development. Prior to joining
The FDA has requested that the data in a single study be reformatted. In addition, GlaxoSmithKline (GSK) will conduct a review of other trial data sets taking this
TorreyPines and Eisai have collaborated on the genetics program since 2002, with the most recent agreement between the parties concluding on September 30, 2008. The Alzheimer’s disease genetics
According to the company, the Apex catheter is a high-performance pre-dilatation balloon catheter developed specifically to address physicians’ needs in treating the most challenging atherosclerotic lesions. It is
According to the company, oral tiomolibdate diammonium’s specificity and unique mechanism of action for rapidly lowering toxic ‘free’ copper levels may position the drug as the first available
Under the terms of the agreement, Azur will be responsible for the clinical development program, the regulatory approval process, and the commercialization of the product in the US,
Mr Leach was also appointed as a director to fill the vacancy created by the passing of Zarko Kraljevic in March 2008. Mr Kay will remain the non-executive
The trial is said to be the first to investigate the combination of two oral antiviral molecules in the absence of interferon. The initial study will evaluate the